U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT06873789) titled 'A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors' on March 11.
Brief Summary: This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors.
Study Start Date: April 24
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Advanced Solid Tumors
Metastatic Solid Tumors
Intervention:
DRUG: INCB177054
INCB177054 will be administered at protocol defined dose.
DRUG: Retifanlimab
Retifanlimab will be administered at protocol defined dose.
Recruitment Status: NOT_YET_RECRUITING...